Marinus Pharmaceuticals, Inc. (MRNS)
NASDAQ: MRNS · Real-Time Price · USD
0.309
+0.002 (0.49%)
At close: Nov 20, 2024, 4:00 PM
0.301
-0.008 (-2.46%)
Pre-market: Nov 21, 2024, 6:56 AM EST
Marinus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 31.47 | 30.99 | 25.48 | 15.35 | 1.72 | - | Upgrade
|
| Revenue Growth (YoY) | 1.63% | 21.63% | 66.03% | 793.19% | - | - | Upgrade
|
| Cost of Revenue | 102.48 | 101.32 | 81.42 | 75 | 50.51 | 42.27 | Upgrade
|
| Gross Profit | -71.01 | -70.33 | -55.94 | -59.65 | -48.79 | -42.27 | Upgrade
|
| Selling, General & Admin | 63.27 | 61.15 | 56.85 | 37.28 | 19.15 | 12.16 | Upgrade
|
| Research & Development | -11.66 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 51.61 | 61.15 | 56.85 | 37.28 | 19.15 | 12.16 | Upgrade
|
| Operating Income | -122.62 | -131.49 | -112.79 | -96.93 | -67.94 | -54.42 | Upgrade
|
| Interest Expense | -17.1 | -16.9 | -10.67 | -2.58 | - | - | Upgrade
|
| Interest & Investment Income | 4.92 | 8.11 | 2.35 | 0.08 | 0.5 | 0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.33 | 1.39 | -1.87 | 0.9 | -0.04 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -134.48 | -138.88 | -122.97 | -98.53 | -67.48 | -54.12 | Upgrade
|
| Gain (Loss) on Sale of Assets | -4 | -4 | 107.38 | - | - | - | Upgrade
|
| Asset Writedown | -0.06 | -0.06 | -0.83 | -0.24 | - | - | Upgrade
|
| Pretax Income | -140.49 | -142.94 | -16.43 | -98.78 | -67.48 | -54.12 | Upgrade
|
| Income Tax Expense | - | -1.54 | 3.39 | - | - | - | Upgrade
|
| Net Income | -140.49 | -141.41 | -19.82 | -98.78 | -67.48 | -54.12 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 8.88 | - | Upgrade
|
| Net Income to Common | -140.49 | -141.41 | -19.82 | -98.78 | -76.36 | -54.12 | Upgrade
|
| Shares Outstanding (Basic) | 57 | 54 | 39 | 37 | 27 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 57 | 54 | 39 | 37 | 27 | 14 | Upgrade
|
| Shares Change (YoY) | 12.09% | 37.56% | 6.47% | 34.57% | 100.10% | 33.30% | Upgrade
|
| EPS (Basic) | -2.47 | -2.63 | -0.51 | -2.69 | -2.80 | -3.97 | Upgrade
|
| EPS (Diluted) | -2.47 | -2.63 | -0.51 | -2.69 | -2.80 | -3.97 | Upgrade
|
| Free Cash Flow | - | -118.12 | -114.66 | -58.37 | -60.91 | -49.02 | Upgrade
|
| Free Cash Flow Per Share | - | -2.20 | -2.93 | -1.59 | -2.23 | -3.60 | Upgrade
|
| Gross Margin | -225.68% | -226.96% | -219.57% | - | - | - | Upgrade
|
| Operating Margin | -389.70% | -424.30% | -442.69% | -631.68% | -3954.42% | - | Upgrade
|
| Profit Margin | -446.49% | -456.31% | -77.78% | -643.70% | -4444.41% | - | Upgrade
|
| Free Cash Flow Margin | - | -381.17% | -450.04% | -380.36% | -3545.52% | - | Upgrade
|
| EBITDA | -118.57 | -126.13 | -111.41 | -96.58 | -67.6 | -54.14 | Upgrade
|
| D&A For EBITDA | 4.05 | 5.36 | 1.37 | 0.36 | 0.33 | 0.28 | Upgrade
|
| EBIT | -122.62 | -131.49 | -112.79 | -96.93 | -67.94 | -54.42 | Upgrade
|
| Revenue as Reported | 31.47 | 30.99 | 25.48 | 15.35 | 1.72 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.